03Vaxcyte reports mixed comparator results in vaccine trial
Vaxcyte reported Phase III results for its 31-serotype pneumococcal vaccine candidate VAX-31 on Monday. In 3,572 adults, it met non-inferiority criteria for all 20 serotypes shared with Prevnar 20, but 17 of 19 shared with Capvaxive. The company plans a US regulatory filing.
Useful?